Please login to the form below

Not currently logged in
Email:
Password:

Severe Asthma

This page shows the latest Severe Asthma news and features for those working in and with pharma, biotech and healthcare.

AZ, Amgen’s investigational asthma drug comes good in phase 3

AZ, Amgen’s investigational asthma drug comes good in phase 3

According to AZ, over two-thirds of patients with severe asthma have T2 inflammation-driven asthma, which includes the eosinophilic phenotype, and typically elevated eosinophil levels. ... Nucala (mepolizumab) is authorised as a treatment for severe

Latest news

More from news
Approximately 0 fully matching, plus 109 partially matching documents found.

Latest Intelligence

  • Exploring the potential of eosinophils Exploring the potential of eosinophils

    Working as a clinician at this time meant he was caring for patients with allergies and asthma, in particular severe asthma. ... IL5 biologic treatments would help patients with severe asthma.

  • A snapshot of… Enterprise Therapeutics A snapshot of… Enterprise Therapeutics

    In severe situations the mucus actually forms plugs which block the airways and significantly reduce lung function. ... In addition, we have the opportunity to evaluate the clinical efficacy of our drugs in other muco-obstructive lung diseases such as

  • GSK forges ahead with its dynamic COPD and asthma portfolio GSK forges ahead with its dynamic COPD and asthma portfolio

    You would imagine coronavirus would be one of those threats.”. GSK is trialling its biologic anti IL-5 drug mepolizumab, licensed for severe asthma, in eosinophilic COPD with a new phase ... Research focus. “I set up and ran a severe asthma clinic

  • The long and winding road to asthma breakthroughs The long and winding road to asthma breakthroughs

    Severe eosinophilic asthma (SEA) impacts between 5-10% of the population but they, and other severe asthma subtypes, represent 50% of the cost of asthma care expenditure. ... and adults under the age of 45 living with asthma in Europe and approximately 10

  • AstraZeneca: building a new ‘open innovation’ pharma company AstraZeneca: building a new ‘open innovation’ pharma company

    AstraZeneca launched five significant new medicines in 2017: immunotherapy Iminzi, Calquence for mantle cell lymphoma, Qtern in type 2 diabetes, Bevespi Aerosphere in COPD and Fasenra for severe asthma.

More from intelligence
Approximately 0 fully matching, plus 12 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • Article

    Inhale, Exhale: The struggle of living with Severe Asthma and Severe Eosinophilic Asthma. ... Head of “Living With”, Mariel Metcalfe, discusses the nature of severe asthma and severe eosinophilic asthma, and some key findings from recent studies

  • Severe Asthma Patient Story

    020 8581 2040. Address:. 1st &2nd floor,. 190 Chiswick High Road,. London. W4 1PP.

  • Research Partnership

    Inhale, Exhale: The struggle of living with Severe Asthma and Severe Eosinophilic Asthma.

More from PMHub
Approximately 2 fully matching, plus 1 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Viseven

Viseven is a full cycle digital agency with 10 years expertise in developing content for the global pharmaceutical market delivering...

Latest intelligence

2020 - a year to remember or forget?
2020 and the Covid pandemic brought immense challenges, and the need for change felt like it happened overnight. What have we learned and what does the future of agency working...
Gilead Headquarters
The search for effective drug treatments for COVID-19
PME talks to Julian Cole, Senior Director, Medical Affairs at Gilead Sciences...
PME Jan cover
AstraZeneca’s focus on diagnosing and managing chronic kidney disease
People living with chronic kidney disease are in urgent need of new and improved approaches to diagnosis and care...

Infographics